ANI Pharmaceuticals (ANIP) stock surged 6.49% in pre-market trading on Friday following the company's announcement of record second-quarter 2025 financial results and raised full-year guidance. The pharmaceutical company significantly outperformed market expectations, demonstrating strong momentum in its business operations.

For the second quarter of 2025, ANI Pharmaceuticals reported adjusted earnings per share (EPS) of $1.80, substantially beating the analyst estimate of $1.39. The company's sales for the quarter reached $211.371 million, surpassing the expected $187.797 million. This impressive performance underscores the company's ability to execute its strategic initiatives effectively and capitalize on market opportunities.

In light of these strong results, ANI Pharmaceuticals has raised its outlook for the full year 2025. The company now expects annual revenues in the range of $818 million to $843 million, up from previous estimates. Additionally, the adjusted EPS guidance has been increased to a range of $6.98 to $7.35, compared to the earlier FactSet estimate of $6.53. This upward revision in guidance reflects management's confidence in the company's growth trajectory and operational efficiency, further fueling investor optimism and contributing to the stock's pre-market rally.